US Patent 7,994,185: Vemurafenib Compound Scope, Claims, Expiration, and Generic Risk

US Patent 7,994,185 protects vemurafenib, also known as PLX4032 and marketed by Roche as Zelboraf. Its strongest protection is the specific active pharmaceutical ingredient, vemurafenib mesylate, together with pharmaceutical compositions and melanoma treatment methods directed to tumors carrying a BRAF V600E mutation. The patent is listed in the FDA Orange Book with an expiration date of March 2, 2028, subject to any applicable legal adjustment or terminal-disclaimer analysis.[1]

What drug does US Patent 7,994,185 protect?

The patent protects vemurafenib and pharmaceutically acceptable salts of the compound. Claim 16 expressly identifies the mesylate salt as:

“N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide mesylate.”

This compound is vemurafenib.

Item	Patent-related information
Active ingredient	Vemurafenib
Development code	PLX4032
Brand	Zelboraf
Drug class	BRAF kinase inhibitor
Key molecular target	Mutant BRAF, especially BRAF V600E
Patent	US 7,994,185
Patent grant date	August 9, 2011
Patent holder/developer	Plexxikon, later commercialized through Roche/Genentech
FDA approval	August 17, 2011
Dosage form	Oral tablets
FDA indication	Unresectable or metastatic melanoma with BRAF V600E mutation
Orange Book patent expiration	March 2, 2028

The patent is directed to a small-molecule kinase inhibitor, not a biologic. Biosimilar approval pathways therefore do not apply. Any follow-on product would generally proceed through the abbreviated new drug application, or ANDA, pathway if it meets FDA generic-drug requirements.

What are the principal claim categories in US 7,994,185?

The supplied claims divide into four legal categories: chemical compounds, salts, pharmaceutical compositions, and therapeutic methods.

Compound claims

Claims 1, 6, and 11 cover chemical subject matter defined by structural formulas or salt forms. The supplied text does not reproduce the chemical drawings associated with claims 1, 6, and 11. Claim 16, however, identifies the principal commercial compound expressly and removes ambiguity about the covered species.

The compound claims are composition-of-matter claims. They do not depend on a particular manufacturer, tablet strength, excipient, manufacturing route, or therapeutic indication unless those limitations appear in the corresponding formula or claim language.

Composition-of-matter claims are generally the most valuable patent claims because they can reach:

The active ingredient itself.
The ingredient in different formulations.
The ingredient made by different synthetic routes.
The ingredient used for indications outside the claimed method-of-use language, subject to claim construction and other applicable rights.
Generic products containing the claimed active compound.

Salt claims

Claims 11 and 16 are particularly important because they cover a pharmaceutically acceptable salt and specifically the mesylate salt. Vemurafenib is commonly supplied as the mesylate form.

A salt claim can create an independent infringement issue even when a manufacturer argues that its process, formulation, or crystal form differs from the originator’s process. If the finished drug contains the claimed salt, the product may fall within the claim regardless of how the salt was manufactured.

Pharmaceutical composition claims

Claims 2, 7, 12, and 17 cover pharmaceutical compositions containing the claimed compound or salt together with one or more pharmaceutically acceptable carriers, diluents, or excipients.

These claims are broad at the functional level. They do not appear limited to a particular excipient system, tablet coating, dissolution profile, particle size, or manufacturing process. Claims 3, 8, 13, and 18 narrow the composition category to a unit dosage form.

The composition claims can cover:

Tablets.
Capsules.
Powder-filled dosage forms.
Other unit-dose oral products.
Pharmaceutical compositions containing vemurafenib mesylate with conventional excipients.

The composition claims do not necessarily establish exclusivity over every formulation attribute. A separate formulation patent would normally be required for specific particle-size distributions, polymorphs, coatings, release profiles, excipient combinations, or manufacturing parameters.

What melanoma treatment methods are protected?

Claims 4, 9, 14, and 19 cover administering an effective amount of the claimed compound or salt to a human suffering from melanoma.

Claims 5, 10, 15, and 20 further limit the treatment to metastatic melanoma having a mutation encoding a V600E amino-acid substitution.

Claim group	Treatment scope
Claims 4, 9, 14, 19	Treatment of human melanoma
Claims 5, 10, 15, 20	Treatment of metastatic melanoma with a BRAF V600E mutation

The method claims are narrower than the compound claims because they require a therapeutic use. They are directed to human treatment and an effective amount of the claimed compound.

The V600E limitation is commercially important. Zelboraf approval required identification of BRAF V600E mutation status through an FDA-approved test. The approved label also distinguishes BRAF V600E-positive disease from other BRAF alterations.[2]

How strong is the patent estate for vemurafenib?

The strongest asset in US 7,994,185 is the composition-of-matter protection for vemurafenib and its mesylate salt. The patent does not rely solely on a method-of-use claim. It includes compound and salt claims that can reach the active ingredient independently of the indication.

Protection type	Commercial significance	Relative strength
Specific vemurafenib compound	Reaches the active ingredient	High
Mesylate salt	Reaches the marketed salt form	High
Broad structural formulas	May cover related chemical species	Depends on omitted formula and claim construction
Pharmaceutical compositions	Reaches products containing the compound	Moderate to high
Unit dosage forms	Reaches dosage-form products	Moderate
Melanoma treatment	Covers human therapeutic use	Moderate
BRAF V600E metastatic melanoma	Matches the original approved use	Moderate to high

The compound claims are less dependent on proof of clinical use than method claims. A generic manufacturer could face infringement exposure from the active ingredient alone, even if it disputes the scope of the method claims.

The exact breadth of claims 1, 6, and 11 cannot be assessed solely from the text supplied because the structural formulas are omitted. Claim 16 provides a complete, specific species claim and is sufficient to identify the marketed molecule.

When does US Patent 7,994,185 lose exclusivity?

The Orange Book lists March 2, 2028, as the patent expiration date for US 7,994,185.[1] The relevant exclusivity timeline is:

Date	Event
March 2, 2007	International-priority and patent-family timeline associated with the vemurafenib compound disclosures
August 9, 2011	US 7,994,185 granted
August 17, 2011	FDA approved Zelboraf
August 17, 2016	Five-year new chemical entity exclusivity ended
March 2, 2028	Orange Book-listed patent expiration
After patent expiry	Potential launch date for a non-infringing or successfully challenged ANDA product

The five-year NCE exclusivity expired in 2016. NCE exclusivity prevented FDA approval of an ANDA or 505(b)(2) application relying on the drug’s approval during that period, but it did not extend the patent term.

Patent expiry and FDA exclusivity are separate. After NCE exclusivity ended, an ANDA applicant could file a Paragraph IV certification against a listed patent, subject to the Hatch-Waxman framework.

What is the Orange Book status of vemurafenib?

Zelboraf is an FDA-approved small-molecule product. The FDA Orange Book lists US 7,994,185 as a patent associated with the reference product.[1]

Orange Book listing does not itself establish that every claim in the patent is valid or infringed. It creates a statutory patent-notice framework for ANDA applicants. A generic applicant generally must certify to each listed patent as required by the FDA application process.

The principal regulatory implications are:

A Paragraph IV certification can create a patent dispute before the listed patent expires.
The patent holder may file an infringement action within the statutory period after receiving notice.
A timely infringement action can trigger a 30-month stay of final FDA approval, subject to statutory exceptions and court action.
A generic applicant may also certify that it will not market until patent expiry, resulting in a Paragraph III certification.

Which companies are challenging vemurafenib patent rights?

The supplied record does not identify a Paragraph IV notice letter, ANDA applicant, district-court complaint, or settlement agreement directed to US 7,994,185.

No biosimilar challenge is relevant because vemurafenib is a chemically synthesized small molecule. Competitive risk would come from an ANDA applicant, an authorized generic, or a non-infringing alternative product rather than a biosimilar sponsor.

A Paragraph IV challenge could attack the patent on several grounds:

Anticipation.
Obviousness.
Lack of written description.
Lack of enablement.
Indefiniteness.
Non-infringement based on the chemical form, salt, or product composition.
Non-infringement of the V600E-specific method claims.

The specific compound and mesylate claims would likely be the central targets in any challenge because they provide the broadest product-level protection.

What formulation patents protect vemurafenib?

US 7,994,185 contains composition claims, but the supplied claims do not identify a separate proprietary formulation technology. The claims refer generally to pharmaceutically acceptable carriers, diluents, and excipients and to unit dosage forms.

That language differs from a narrow formulation patent covering:

A particular crystalline polymorph.
A defined particle-size distribution.
A solid dispersion.
A specific tablet coating.
A dissolution specification.
A fixed excipient ratio.
A process-controlled granulation method.
A combination product.

The patent therefore appears to protect the presence of vemurafenib or vemurafenib mesylate in a pharmaceutical dosage form, rather than a narrowly defined formulation platform.

A generic company could still need to evaluate separate family members, continuation patents, formulation patents, manufacturing patents, and regulatory exclusivities before launching.

What manufacturing and intellectual-property barriers affect generic entry?

Vemurafenib presents several potential manufacturing barriers even after basic compound protection expires.

Chemical synthesis

A generic manufacturer must develop a reproducible route to the substituted thiazole compound and control impurities, residual solvents, regioisomers, and salt formation. Process patents can create risk even where the core compound patent has expired.

Salt and solid-state control

The mesylate salt requires control of stoichiometry, crystallization, particle properties, and stability. A different salt or solid form may avoid a particular claim but could require separate FDA bridging and pharmaceutical-development work.

Bioequivalence

The generic product must demonstrate bioequivalence to the reference listed drug. For an immediate-release oral product, the sponsor would normally need to establish comparable pharmacokinetic exposure and meet FDA quality requirements.

Diagnostic alignment

The approved use is linked to BRAF mutation status. A generic label and distribution strategy would need to remain consistent with the reference product’s labeling and any applicable FDA requirements for companion diagnostic use.

What patent litigation or settlement issues affect launch timing?

A Paragraph IV filing could produce litigation before March 2, 2028. If the patent holder files a timely infringement action, the 30-month stay can delay approval, although the stay does not automatically prevent commercial launch after other legal barriers expire.

The supplied information establishes no settlement agreement, authorized-generic arrangement, or agreed early-entry date. In the absence of a confirmed settlement, the commercial launch scenarios are:

Scenario	Likely result
Paragraph III certification	Approval delayed until patent expiry
Paragraph IV certification with no suit	Approval may proceed after statutory notice periods
Paragraph IV certification followed by litigation	Approval may be delayed by litigation and any 30-month stay
Successful invalidity or non-infringement judgment	Earlier approval or launch may become possible
Settlement with licensed entry	Launch date depends on the agreement
Non-infringing alternative salt or formulation	Requires separate infringement and FDA analysis

How does vemurafenib compare with competing BRAF inhibitors?

Vemurafenib competes primarily with dabrafenib, often used with trametinib, and encorafenib, used with binimetinib. These products have different patent estates and combination-product exposure.

Product	Active ingredient	Principal target	Commercial distinction
Zelboraf	Vemurafenib	BRAF V600E/V600K	First-generation BRAF inhibitor; strong historical use in BRAF-mutant melanoma
Tafinlar	Dabrafenib	BRAF V600	Often combined with trametinib
Braftovi	Encorafenib	BRAF V600	Often combined with binimetinib

Vemurafenib’s patent risk is concentrated in the compound and mesylate claims of US 7,994,185. Competitor products are not direct substitutes for purposes of patent infringement because they use different active ingredients. They nevertheless reduce commercial exposure if they capture patients before or after generic vemurafenib entry.

What is the revenue exposure from US 7,994,185?

The patent’s commercial exposure is Zelboraf revenue in the United States. Roche financial reporting does not always present Zelboraf revenue as a separately disclosed, current standalone line item. The product’s economic value has declined from its early post-launch period because of competition from other BRAF/MEK regimens and changing melanoma treatment patterns.

The principal value drivers before patent expiry are:

Continued US demand for vemurafenib.
The absence or timing of an ANDA challenger.
Any authorized-generic strategy.
Prescriber preference among BRAF/MEK combinations.
Use in other approved BRAF-mutant cancers.
The strength of any separate formulation or process patents.

The March 2028 Orange Book date remains the key US product-exclusivity milestone, but actual generic entry could occur earlier if a challenger prevails or reaches a settlement.

Key Takeaways

US 7,994,185 protects vemurafenib, including the commercially relevant mesylate salt.
Claim 16 expressly identifies vemurafenib mesylate.
The patent includes composition-of-matter, pharmaceutical-composition, unit-dose, and melanoma-treatment claims.
The method claims specifically cover metastatic melanoma with a BRAF V600E mutation.
FDA approved Zelboraf on August 17, 2011.
Five-year NCE exclusivity ended on August 17, 2016.
The Orange Book-listed patent expiration date is March 2, 2028.
Vemurafenib is a small molecule, so biosimilar risk does not apply.
Any generic entrant would likely use the ANDA pathway and evaluate Paragraph III or Paragraph IV certification.
The supplied record does not establish a Paragraph IV challenger, patent litigation case, settlement, or authorized-generic agreement.
The exact scope of claims 1, 6, and 11 depends on structural formulas not reproduced in the supplied claim text.

FAQs

Is US 7,994,185 the main patent for Zelboraf?

It is a principal US patent because it covers vemurafenib and its mesylate salt at the composition-of-matter level, in addition to compositions and melanoma treatment methods.

Does US 7,994,185 cover dabrafenib or encorafenib?

No. The patent is directed to vemurafenib-related compounds. Dabrafenib and encorafenib are different active ingredients with separate patent estates.

Can a generic company launch vemurafenib before March 2, 2028?

Potentially, but only through a successful patent challenge, a license or settlement, an authorized-generic arrangement, or a product design that does not infringe enforceable claims and satisfies FDA requirements.

Is vemurafenib protected by a biologic exclusivity period?

No. Vemurafenib is a chemically synthesized small molecule. Its relevant regulatory protections are small-molecule exclusivities and listed patents, not biologic reference-product exclusivity.

Does the V600E method claim cover all melanoma treatment?

No. The narrower claims require metastatic melanoma with a mutation encoding a V600E amino-acid substitution. The broader method claims recite treatment of melanoma but remain subject to the other limitations in the claim language.

References

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book, Zelboraf (vemurafenib), patent information. FDA.
U.S. Food and Drug Administration. (2011). Zelboraf prescribing information. Genentech USA, Inc.
U.S. Patent No. 7,994,185. (2011). N-substituted thiazole compounds as inhibitors of kinases. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2011, August 17). FDA approves Zelboraf for late-stage melanoma. FDA.
U.S. Food and Drug Administration. (2011). Zelboraf approval letter. FDA.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-001	May 29, 2013		RX	Yes	No	7,994,185*PED	⤷ Start Trial			Y		⤷ Start Trial
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-002	May 29, 2013		RX	Yes	Yes	7,994,185*PED	⤷ Start Trial			Y		⤷ Start Trial
Novartis	TAFINLAR	dabrafenib mesylate	TABLET, FOR SUSPENSION;ORAL	217514-001	Mar 16, 2023		RX	Yes	Yes	7,994,185*PED	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	071617	⤷ Start Trial
Australia	2009244491	⤷ Start Trial
Brazil	PI0912541	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,994,185

Which drugs does patent 7,994,185 protect, and when does it expire?

Summary for Patent: 7,994,185